Opiate use after total hip arthroplasty for metastatic bone disease.

Authors

null

Gayathri Vijayakumar

Rush University Medical Center, Chicago, IL

Gayathri Vijayakumar , Dylan Vance , Matthew W. Colman , Steven Gitelis , Kyle Sweeney , Alan T. Blank

Organizations

Rush University Medical Center, Chicago, IL, University of Kansas Medical Center, Kansas City, KS

Research Funding

No funding received
None.

Background: Metastatic bone disease (MBD) commonly affects the hip and surgical intervention including total hip arthroplasty (THA) may be indicated for pain relief or to improve function. Following THA, patients are often prescribed short courses of opioids for postoperative pain relief. This study investigated postoperative opioid use following THA in MBD patients. Methods: This was a retrospective review of patients using opioids preoperatively who underwent THA for MBD at two institutions between 2009 and 2022. Preoperative and postoperative opioid usage at 6 weeks and 90 days were quantified through calculating daily morphine milligram equivalents (MME) and compared using the sign test. Results: Nineteen primary THA and 11 THA with complex acetabular reconstruction were included. At six weeks, 26 (86.7%) patients were utilizing opiates and at ninety days 23 (76.7%) patients were utilizing opiates. There was a statistically significant difference between median daily preoperative MME compared to daily MME at ninety days (p < 0.001). The only statistically significant association with opioid use at 90 days was opioid use at 6 weeks. Conclusions: To our knowledge, this is the first paper evaluating postoperative opioid use following primary THA in MBD patients. After THA in the setting of MBD, patients exhibit decreased postoperative opioid use.

Postoperative opioid use.

Opiate Use at 6 weeks26 (86.7%)p value
Daily MME at 6 weeks, median (IQR)45 (18.75-101.25)
Delta MME preop and 6 weeks, median (IQR)0 (*-12.75-41.25) p = 0.186
Opiate Use at 90 days23 (76.7%)
Daily MME at 90 days, median (IQR)30 (8.75-122.50)
Delta MME preop and 90 days, median (IQR)10 (*-12.75 – 63.75) p < 0.001

MME, morphine milligram equivalent; IQR, interquartile range; *negative value in IQR denotes greater opioid use compared to preoperative opioid use; statistically significant p value is bolded.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e24132)

DOI

10.1200/JCO.2023.41.16_suppl.e24132

Abstract #

e24132

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Quality Care Symposium

Opioid tapering and discontinuation for head and neck cancer (HNC) survivors.

First Author: Talya Salz

Abstract

2022 ASCO Annual Meeting

Association of opioid use with response to immune checkpoint inhibitors.

First Author: Michael Weinfeld

Abstract

2021 ASCO Annual Meeting

Analysis of opioid and adjunctive pain medication prescriptions in lung cancer patients.

First Author: Benjamin Aaron Bleiberg

Abstract

2015 Genitourinary Cancers Symposium

Opioid use among prostate cancer patients with bone metastases.

First Author: Avin Yaldo